Lymphocytic choriomeningitis virus (LCMV) exhibits natural tropism for dendritic cells and represents the prototypic infection that elicits protective CD8+ T cell (cytotoxic T lymphocyte (CTL)) immunity. Here we have harnessed the immunobiology of this arenavirus for vaccine delivery. By using producer cells constitutively synthesizing the viral glycoprotein (GP), it was possible to replace the gene encoding LCMV GP with vaccine antigens to create replication-defective vaccine vectors. These rLCMV vaccines elicited CTL responses that were equivalent to or greater than those elicited by recombinant adenovirus 5 or recombinant vaccinia virus in their magnitude and cytokine profiles, and they exhibited more effective protection in several models. In contrast to recombinant adenovirus 5, rLCMV failed to elicit vector-specific antibody immunity, which facilitated re-administration of the same vector for booster vaccination. In addition, rLCMV elicited T helper type 1 CD4+ T cell responses and protective neutralizing antibodies to vaccine antigens. These features, together with low seroprevalence in humans, suggest that rLCMV may show utility as a vaccine platform against infectious diseases and cancer.
At a glance
- An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J. Exp. Med. 205, 63–77 (2008). et al.
- Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity. Vaccine 25, 2120–2127 (2007). et al.
- Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major . Nat. Med. 13, 843–850 (2007). et al.
- Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector. AIDS 18, 1213–1216 (2004). et al.
- Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 441, 239–243 (2006). et al.
- Arenaviridae: The viruses and their replication. in Fields Virology (eds. Knipe, D.M. and Howley, P.M.) 1635–1668 (Lippincott Williams & Wilkins, Philadelphia, Pennsylvania, 2001). , &
- Differential regulation of antiviral T-cell immunity results in stable CD8+ but declining CD4+ T-cell memory. Nat. Med. 7, 913–919 (2001). , &
- Kinetics of protective antibodies are determined by the viral surface antigen. J. Clin. Invest. 114, 988–993 (2004). et al.
- Recombinant lymphocytic choriomeningitis virus expressing vesicular stomatitis virus glycoprotein. Proc. Natl. Acad. Sci. USA 100, 7895–7900 (2003). , , &
- Recovery of an arenavirus entirely from RNA polymerase I/II-driven cDNA. Proc. Natl. Acad. Sci. USA 103, 4663–4668 (2006). , , &
- Persistence of lymphocytic choriomeningitis virus at very low levels in immune mice. Proc. Natl. Acad. Sci. USA 96, 11964–11969 (1999). et al.
- Rapid functional exhaustion and deletion of CTL following immunization with recombinant adenovirus. J. Immunol. 174, 4559–4566 (2005). , , &
- Long-lived virus-reactive memory T cells generated from purified cytokine-secreting T helper type 1 and type 2 effectors. J. Exp. Med. 205, 53–61 (2008). et al.
- Antiviral protection by vesicular stomatitis virus-specific antibodies in alpha/beta interferon receptor-deficient mice. J. Virol. 69, 2153–2158 (1995). et al.
- Organ-specific regulation of the CD8 T cell response to Listeria monocytogenes infection. J. Immunol. 166, 3402–3409 (2001). et al.
- Recombinant Listeria monocytogenes as a live vaccine vehicle and a probe for studying cell-mediated immunity. Immunol. Rev. 158, 147–157 (1997). , , , &
- CD8 T cell ignorance or tolerance to islet antigens depends on antigen dose. Proc. Natl. Acad. Sci. USA 96, 12703–12707 (1999). et al.
- T cell receptor antagonist peptides induce positive selection. Cell 76, 17–27 (1994). et al.
- Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo . J. Immunol. 161, 2187–2194 (1998). et al.
- Dendritic cells: versatile controllers of the immune system. Nat. Med. 13, 1155–1159 (2007).
- Inducible transgenic mice reveal resting dendritic cells as potent inducers of CD8+ T cell tolerance. Immunity 18, 713–720 (2003). , , &
- Immunosuppression and resultant viral persistence by specific viral targeting of dendritic cells. J. Exp. Med. 192, 1249–1260 (2000). et al.
- Z/EG, a double reporter mouse line that expresses enhanced green fluorescent protein upon Cre-mediated excision. Genesis 28, 147–155 (2000). , , , &
- Induction of protective cytotoxic T cell responses in the presence of high titers of virus-neutralizing antibodies: implications for passive and active immunization. J. Exp. Med. 187, 649–654 (1998). et al.
- Prevalence of antibodies to lymphocytic choriomeningitis virus in blood donors in southeastern France. Transfusion 47, 172–173 (2007). , &
- Lymphocytic choriomeningitis virus infection in a province of Spain: analysis of sera from the general population and wild rodents. J. Med. Virol. 70, 273–275 (2003). , , , &
- Low prevalence of antibodies against the zoonotic agents Brucella abortus, Leptospira spp., Streptococcus suis serotype II, hantavirus, and lymphocytic choriomeningitis virus among veterinarians and pig farmers in the southern part of The Netherlands. Vet. Q. 21, 50–54 (1999). et al.
- Prevalence of serum antibodies against lymphocytic choriomeningitis virus in selected populations from two U.S. cities. J. Med. Virol. 38, 27–31 (1992). et al.
- Transmission of lymphocytic choriomeningitis virus by organ transplantation. N. Engl. J. Med. 354, 2235–2249 (2006). et al.
- Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys. J. Virol. 79, 2956–2963 (2005). et al.
- Decreased tumor surveillance after adoptive T-cell therapy. Cancer Res. 67, 7467–7476 (2007). et al.
- Induction of potent antitumor CTL responses by recombinant vaccinia encoding a melan-A peptide analogue. J. Immunol. 164, 1125–1131 (2000). et al.
- DNA vaccines encoding retrovirus-based virus-like particles induce efficient immune responses without adjuvant. Vaccine 24, 2643–2655 (2006). et al.
- Fully detargeted polyethylene glycol-coated adenovirus vectors are potent genetic vaccines and escape from pre-existing anti-adenovirus antibodies. Mol. Ther. 16, 154–162 (2008). et al.
- Dissociation of proteasomal degradation of biosynthesized viral proteins from generation of MHC class I-associated antigenic peptides. J. Immunol. 160, 4859–4868 (1998). et al.
- Anti-viral protection and prevention of lymphocytic choriomeningitis or of the local footpad swelling reaction in mice by immunization with vaccinia-recombinant virus expressing LCMV-WE nucleoprotein or glycoprotein. Eur. J. Immunol. 19, 417–424 (1989). et al.
- Immunodominance of an antiviral cytotoxic T cell response is shaped by the kinetics of viral protein expression. J. Immunol. 171, 5415–5422 (2003). et al.
- Tolerance induction in double specific T-cell receptor transgenic mice varies with antigen. Nature 342, 559–561 (1989). , , , &
- HLA-A2.1-restricted education and cytolytic activity of CD8+ T lymphocytes from β2 microglobulin (β2m) HLA-A2.1 monochain transgenic H-2Db β2m double knockout mice. J. Exp. Med. 185, 2043–2051 (1997). et al.
- Toll-like receptor ligands modulate dendritic cells to augment cytomegalovirus- and HIV-1-specific T cell responses. J. Immunol. 171, 4320–4328 (2003). et al.
- Supplementary Text and Figures (2M)
Supplementary Figures 1–8